A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer.

被引：0
|
作者：
Calvo, E
Rowinsky, EK
Tolcher, AW
Chu, QS
Beeram, M
Forero, L
Mettinger, KL
Eastham, E
Goetz, AD
Patnaik, A
机构：
[1] Canc Therapy & Res Ctr S Texas, San Antonio, TX USA
[2] SuperGen Inc, Dublin, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2099
引用
收藏
页码：151S / 151S
页数：1
相关论文
共 50 条
  • [31] Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.
    Beijnen, JH
    Rademaker-Lakhai, JM
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    De Rijke, TM
    Jimeno, JM
    Lazaro, LL
    Martin, JAL
    Schellens, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 146S - 146S
  • [32] Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Schellens, JH
    Rademaker, JL
    Horenblas, S
    Meinhardt, W
    Stokvis, E
    De Reijke, TM
    Jimeno, JM
    Lazaro, LL
    Martin, JAL
    Beijnen, JH
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3694S - 3694S
  • [33] Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
    Vasilios Karavasilis
    Epaminontas Samantas
    Georgia-Angeliki Koliou
    Anna Kalogera-Fountzila
    George Pentheroudakis
    Ioannis Varthalitis
    Helena Linardou
    Grigorios Rallis
    Maria Skondra
    Georgios Papadopoulos
    George Papatsibas
    Joseph Sgouros
    Athina Goudopoulou
    Konstantine T. Kalogeras
    Christos Dervenis
    Dimitrios Pectasides
    George Fountzilas
    Targeted Oncology, 2018, 13 : 715 - 724
  • [34] Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
    Karavasilis, Vasilios
    Samantas, Epaminontas
    Koliou, Georgia-Angeliki
    Kalogera-Fountzila, Anna
    Pentheroudakis, George
    Varthalitis, Ioannis
    Linardou, Helena
    Rallis, Grigorios
    Skondra, Maria
    Papadopoulos, Georgios
    Papatsibas, George
    Sgouros, Joseph
    Goudopoulou, Athina
    Kalogeras, Konstantine T.
    Dervenis, Christos
    Pectasides, Dimitrios
    Fountzilas, George
    TARGETED ONCOLOGY, 2018, 13 (06) : 715 - 724
  • [35] A Phase I study of 'Tomudex' and gemcitabine in advanced cancer
    Cripps, C
    Batist, G
    Dahrouge, S
    Fry, D
    McQuillan, A
    Kolendowicz, R
    Abugaber, AA
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S289 - S289
  • [36] Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    Ando, M
    Eguchi, K
    Shinkai, T
    Tamura, T
    Ohe, Y
    Yamamoto, N
    Kurata, T
    Kasai, T
    Ohmatsu, H
    Kubota, K
    Sekine, I
    Hojo, N
    Matsumoto, T
    Kodama, T
    Kakinuma, R
    Nishiwaki, Y
    Saijo, N
    BRITISH JOURNAL OF CANCER, 1997, 76 (11) : 1494 - 1499
  • [37] Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    M Ando
    K Eguchi
    T Shinkai
    T Tamura
    Y Ohe
    N Yamamoto
    T Kurata
    T Kasai
    H Ohmatsu
    K Kubota
    I Sekine
    N Hojo
    T Matsumoto
    T Kodama
    R Kakinuma
    Y Nishiwaki
    N Saijo
    British Journal of Cancer, 1997, 76 : 1494 - 1499
  • [38] PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN (TPT), A-TOPOISOMERASE (TOPO) I-INHIBITOR, IN PATIENTS (PTS) WITH REFRACTORY LEUKEMIAS
    ADJEI, AA
    ROWINSKY, EK
    DONEHOWER, RC
    JONES, RJ
    BURKE, PJ
    GORE, S
    GROCHOW, LB
    KAUFMANN, SH
    BLOOD, 1993, 82 (10) : A443 - A443
  • [39] Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study
    van Gijn, R
    Huinink, WWT
    Rodenhuis, S
    Vermorken, JB
    van Tellingen, O
    Rosing, H
    van Warmerdam, LJC
    Beijnen, JH
    ANTI-CANCER DRUGS, 1999, 10 (01) : 17 - 23
  • [40] Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    Twelves, CJ
    Gardner, C
    Flavin, A
    Sludden, J
    Dennis, I
    de Bono, J
    Beale, P
    Vasey, P
    Hutchison, C
    Macham, MA
    Rodriguez, A
    Judson, I
    Bleehen, NM
    BRITISH JOURNAL OF CANCER, 1999, 80 (11) : 1786 - 1791
12345